We'll know more about the company's medium-term prospects by the end of the year.

With an approved treatment in commercial stages and new drug candidates generating clinical trial results, this biotech has attracted a big Investor.

Crispr Therapeutics Ag (NASDAQ:CRSP) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Biotech company Crispr Therapeutics Ag (NASDAQ:CRSP) shares are up 16% over the past 12 months.

An updated edition of the Feb. 20, 2026, article. Genomics involves a thorough study of genomes (an organism’s complete set of deoxyribonucleic acid or DNA). It involves understanding how genes ...

There are plenty of reasons, though, to be bullish on the stock, not the least of which is its improved cash position. The ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $55.72, moving -1.83% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 0.26%. On ...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its ...

Investors looking for stocks that can turn a modest portfolio into a multimillion-dollar nest egg often find what they're looking for in the biotech industry. For several years, CRISPR Therapeutics ...